

## PROSPECTUS FOR LOYALTY OPTIONS LODGED

Bio-Gene Technology Limited (ASX: BGT, “Bio-Gene” or “the Company”), an agtech development company enabling the next generation of novel insecticides to address insecticide resistance, is pleased to advise that the prospectus for the issue of Loyalty Options has today been lodged with ASIC and released to ASX. The record date for entitlements to Loyalty Options is 7 March 2018.

All Eligible Bio-Gene shareholders, holding Ordinary Shares on the record date, will receive 1 free Loyalty Option for every 5 Shares held. Eligible shareholders will be holders as at 7 March 2018 whose address in the Company’s shareholder register is in Australia or New Zealand.

Each Loyalty Option will be exercisable at any time on or before 4 December 2018 (the Expiry Date) and have an exercise price of 20 cents.

The Company has today also released an Appendix 3B which constitutes the Company applying to ASX for the Loyalty Options offered pursuant to the Prospectus to be admitted to quotation on ASX.

The timetable for the issue of the Loyalty Options is as follows:

ACTION	TIMING/DATE
Lodgement of prospectus with ASIC and release to ASX	1 March 2018
Release to ASX of an Appendix 3B for all possible loyalty options (including if all options on issue are exercised)	
Mail notices to optionholders and ineligible shareholders	
<b>Record Date for entitlement to loyalty options (7:00pm Melbourne time)</b>	<b>7 March 2018</b>
Issue of Loyalty Options*	8 March 2018
Dispatch of copy of Prospectus and holding statements*	9 March 2018
Proposed quotation of loyalty options (subject to satisfaction of quotation conditions imposed by ASX)*	12 March 2018
Loyalty Options expire	4 December 2018

\* The above dates should be regarded as **indicative only**. Subject to the Corporations Act 2001 (Cth), the ASX Listing Rules and other applicable laws, the Company reserves the right to change the above dates or not to proceed with the Offer described in this Prospectus.

Further details are contained in the Loyalty Options prospectus released to ASX today. The Company will make further announcements, including announcing to ASX when the loyalty options have been issued (including a further Appendix 3B) and holding statements dispatched.

**For further information, please contact:**

*Bio-Gene Technology Limited:*

Richard Jagger

Chief Executive Officer

P: 03 9628 4178

E: [bgt.info@bio-gene.com.au](mailto:bgt.info@bio-gene.com.au)

Roger McPherson

CFO & Company Secretary

P: 03 9628 4178

E: [bgt.info@bio-gene.com.au](mailto:bgt.info@bio-gene.com.au)

*Media/investor relations:*

Matthew Wright

NWR Communications

P: 0451 896 420

E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

**About Bio-Gene Technology Ltd**

Bio-Gene is an Australian AgTech development company enabling the next generation of novel insecticides to address the global problems of insecticide resistance and toxicity. Its novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across animal health and crop protection, as well as in public health, and in consumer applications.

The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions.